Changes in Beneficial Ownership · 4
First Tracks Biotherapeutics, Inc.
TRAXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-09042026_080925.xml
Filing details
- Report period
- 2026-09-02
- Issuer
- First Tracks Biotherapeutics, Inc.
- Issuer CIK
- 0002091349
- Trading symbol
- TRAX
Reporting owner 1
- Name
- Ware J. Anthony
- Reporting owner CIK
- 0001715429
- Relationship
- Director
- Address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-02 | M · Form 4 | 39,265 | A | 5.74 | 54,925 | D |
| Common Stock | 2026-09-02 | S · Form 4 | 39,265 | D | 44.7764[F1] | 15,660 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 5.74 | 2026-09-02 | M · Form 4 | 28,571 | D | 0 | [F2] | 2027-08-21 | Common Stock | 28,571 | 0 | D |
| Stock Option (right to buy) | 5.74 | 2026-09-02 | M · Form 4 | 10,694 | D | 0 | [F2] | 2027-08-21 | Common Stock | 10,694 | 0[F3] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.62 to $45.28 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
- F3
- In addition to the shares the Reporting Person owns reported in Table I, the Reporting Person also holds additional options to purchase up to an aggregate of 99,320 shares of common stock and 6,500 restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Ajim Tamboli, Attorney-in-Fact
- Date
- 2026-09-04
Company context
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.